Neuregulin-1(NRG1, 纽兰格林)通过活化ErbB2/ErbB4二聚体具有治疗心衰的作用, 目前已完成临床二期。为避免作为心衰治疗药物时同时激活ErbB3并产生副作用, 因此用NRG1变异体的方法寻找能对ErbB4专一性激活的配体。文章构建了带有不同筛选标记的ErbB2、ErbB3、ErbB4细胞表达质粒, 将ErbB2/ErbB3、ErbB2/ErbB4质粒共转染至CHO细胞, 建立了ErbB2/ErbB3特异性表达和ErbB2/ErbB4特异性表达的细胞株。通过与新生大鼠原代心肌细胞比较, 证明ErbB2/ErbB4细胞株信号传导功能与心肌细胞相似, NRG1可以激活下游的AKT信号途径、PI3K信号途径, 并表现出良好的剂量效应。因此可以通过检测与心肌功能密切相关的下游信号AKT磷酸化水平快速筛选抗心衰药物, 并通过与ErbB2/ErbB3信号激活水平比较鉴定其对心肌细胞的特异性。文章还构建了31个不同的NRG1突变体并在大肠杆菌中成功的表达和纯化。将这些突变体用于刺激两个细胞株, 通过检测AKT磷酸化水平, 发现这些突变体对ErbB2/ErbB3与ErbB2/ErbB4受体的激活能力不同。进一步检测其中5个ErbB2/ErbB4激活特异性发生改变的突变体与两对受体的亲和力, 发现这些突变体和ErbB2/ErbB4与ErbB2/ErbB3受体亲和力的变化有一致性。最终筛选到了4个可以更特异性激活ErbB2/ErbB4受体的突变体作为更有效治疗心衰的候选药物
Neuregulin-1 (NRG1), now in a phase II clinical trial, has beneficial effects on heart failure patients through the activation of ErbB2/ErbB4 receptor pair. To decrease the side effect of NRG1 on activating ErbB3, a mutation screen was carried out to get NRG1 mutants, which have more specific binding to ErbB2/ErbB4 receptor pair. Two CHO stable cell lines were constructed, which express ErbB2/ErbB3 or ErbB2/ErbB4 receptor pair, respectively. The ErbB2/ErbB4 cell line showed similar characteristics in ligand-binding activity and the activation of downstream signaling molecules, such as the AKT and PI3K to the primary neonatal rat ventricular myocytes (NRVM), which endogenously expresses ErbB2/ErbB4. Both cell lines have good dose-response. Thirty-one NRG1 mutants were successfully expressed in Escherichia coli and purified. Their ability to stimulate the downstream signaling was measured by detecting AKT phosphorylation. Some mu-tants showed more specific activation activity in ErbB2/ErbB4 cells. Further study on five of these mutants demonstrated that the change of the activation activity is associated with that of their binding activities to ErbB2/ErbB4 and ErbB2/ErbB3. Four of the candidates are more specific ligands for ErbB2/ErbB4 activation, and thus may serve as more potent drug can-didates for heart failure.
[1] Garratt AN. “To erb-B or not to erb-B...” Neuregulin-1/ErbB signaling in heart development and function. J Mol Cell Cardiol, 2006, 41(2): 215–218.
[2] Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol, 2007, 3: 144.
[3] Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Ram-paul RS, Blamey RW, Robertson JFR, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in inva-sive breast carcinoma. Br J Cancer, 2004, 91(8): 1532– 1542.
[4] Longart M, Chatani-Hinze M, Gonzalez CM, Vullhorst D, Buonanno A. Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons. Brain Res Bull, 2007, 73(4–6): 210–219.
[5] Riese DJ, Gallo RM, Settleman J. Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis. Bioessays, 2007, 29(6): 558–565.
[6] Fitzpatrick VD, Pisacane PI, Vandlen RL, Sliwkowski MX. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett, 1998, 431(1): 102–106.
[7] Garratt AN, Ozcelik C, Birchmeier C. ErbB2 pathways in heart and neural diseases. Trends Cardiovasc Med, 2003, 13(2): 80–86.
[8] Liu XF, Gu XH, Li ZM, Li XF, Li H, Chang JJ, Chen P, Jin J, Xi B, Chen DH, Lai DN, Graham RM, Zhou MD. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral car-diomyopathy. J Am Coll Cardiol, 2006, 48(7): 1438–1447.
[9] Tzahar E, Waterman H, Chen X, Levkowitz G, Karunaga-ran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical net-work of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol, 1996, 16(10): 5276–5287.
[10] Engelman JA, Jänne PA, Mermel C, Pearlberg J, Muko-hara T, Fleet C, Cichowski K, Johnson BE, Cantley LC. ErbB-3 mediates phosphoinositide 3-kinase activity in ge-fitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA, 2005, 102(10): 3788–3793.
[11] Citri A, Yarden Y. EGF–ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol, 2006, 7(7): 505–516.
[12] Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, Kelly RA, Sawyer DB. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/ Akt. J Mol Cell Cardiol, 2003, 35(12): 1473–1479.
[13] Luo C, Xu LF, Zheng SX, Luo XM, Shen JH, Jiang HL, Liu XF, Zhou MD. Computational analysis of molecular basis of 1:1 interactions of NRG1beta wild-type and vari-ants with ErbB3 and ErbB4. Proteins, 2005, 59(4): 742–756.
